Enovis Q2 sales up 23% to $525M; raises adjusted EPS guidance to $2.62-$2.77

Enovis CORP

2024-Q2 EPS reported -$1.65 revenue$1,041,426,000

Q2 net sales $525M (+23% reported, +5% comparable); Recon sales +60% reported.
Reported net loss from cont ops $0.34/sh; adjusted EPS $0.62; adj EBITDA $90M (17.2% of sales, +190bps).
Raised FY2024 adj EPS guidance to $2.62-$2.77 (from $2.52-$2.67); revenue narrowed to $2.08-$2.13B.
Received FDA 510k clearance for Arvis 2.0 Shoulder and Altivate Reverse Glenoid; launches expected Q3 2024.
Opened new manufacturing facility in San Daniele and Business Technology Center in Lisbon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.